Xponance Inc. Grows Position in Intuitive Surgical, Inc. (NASDAQ:ISRG)

Xponance Inc. raised its holdings in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 0.2% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 83,510 shares of the medical equipment provider’s stock after acquiring an additional 165 shares during the period. Xponance Inc.’s holdings in Intuitive Surgical were worth $28,173,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of ISRG. Norges Bank purchased a new position in shares of Intuitive Surgical during the 4th quarter valued at about $915,360,000. WCM Investment Management LLC purchased a new position in shares of Intuitive Surgical during the 4th quarter valued at about $575,536,000. Morgan Stanley increased its stake in Intuitive Surgical by 29.9% in the 4th quarter. Morgan Stanley now owns 5,866,613 shares of the medical equipment provider’s stock worth $1,556,706,000 after purchasing an additional 1,351,002 shares during the period. Barclays PLC increased its stake in Intuitive Surgical by 159.5% in the 2nd quarter. Barclays PLC now owns 1,379,246 shares of the medical equipment provider’s stock worth $471,619,000 after purchasing an additional 847,651 shares during the period. Finally, International Assets Investment Management LLC increased its stake in Intuitive Surgical by 32,360.5% in the 4th quarter. International Assets Investment Management LLC now owns 686,865 shares of the medical equipment provider’s stock worth $231,721,000 after purchasing an additional 684,749 shares during the period. 83.64% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

ISRG has been the topic of a number of analyst reports. StockNews.com cut Intuitive Surgical from a “buy” rating to a “hold” rating in a research note on Thursday, February 29th. Barclays lifted their price target on Intuitive Surgical from $385.00 to $430.00 and gave the stock an “overweight” rating in a research note on Thursday, January 25th. Truist Financial lifted their price objective on Intuitive Surgical from $390.00 to $435.00 and gave the stock a “buy” rating in a research report on Wednesday, January 24th. Citigroup lifted their price objective on Intuitive Surgical from $428.00 to $462.00 and gave the stock a “buy” rating in a research report on Wednesday, April 3rd. Finally, Royal Bank of Canada lifted their price objective on Intuitive Surgical from $400.00 to $432.00 and gave the stock an “outperform” rating in a research report on Wednesday, January 24th. Five equities research analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $375.70.

Insider Buying and Selling at Intuitive Surgical

In other Intuitive Surgical news, VP Fredrik Widman sold 5,041 shares of the firm’s stock in a transaction that occurred on Friday, March 15th. The stock was sold at an average price of $397.07, for a total transaction of $2,001,629.87. Following the completion of the transaction, the vice president now owns 110 shares in the company, valued at approximately $43,677.70. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other news, VP Fredrik Widman sold 5,041 shares of the firm’s stock in a transaction that occurred on Friday, March 15th. The stock was sold at an average price of $397.07, for a total value of $2,001,629.87. Following the completion of the sale, the vice president now directly owns 110 shares of the company’s stock, valued at approximately $43,677.70. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Gary S. Guthart sold 24,325 shares of the firm’s stock in a transaction that occurred on Monday, January 29th. The shares were sold at an average price of $376.06, for a total value of $9,147,659.50. Following the completion of the sale, the chief executive officer now directly owns 9,425 shares of the company’s stock, valued at $3,544,365.50. The disclosure for this sale can be found here. Insiders sold 248,418 shares of company stock worth $95,927,097 in the last quarter. 0.90% of the stock is owned by corporate insiders.

Intuitive Surgical Trading Down 0.4 %

NASDAQ:ISRG traded down $1.54 during trading hours on Thursday, reaching $372.63. 2,264,805 shares of the company traded hands, compared to its average volume of 1,639,282. The business’s 50-day moving average price is $387.56 and its two-hundred day moving average price is $342.39. The stock has a market capitalization of $132.08 billion, a P/E ratio of 74.39, a P/E/G ratio of 5.88 and a beta of 1.36. Intuitive Surgical, Inc. has a 1 year low of $254.85 and a 1 year high of $403.76.

Intuitive Surgical (NASDAQ:ISRG) last released its earnings results on Tuesday, January 23rd. The medical equipment provider reported $1.60 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.48 by $0.12. The firm had revenue of $1.93 billion during the quarter, compared to analysts’ expectations of $1.89 billion. Intuitive Surgical had a return on equity of 13.11% and a net margin of 25.24%. The firm’s revenue was up 16.6% on a year-over-year basis. During the same quarter last year, the business posted $0.91 earnings per share. As a group, equities analysts anticipate that Intuitive Surgical, Inc. will post 4.93 EPS for the current year.

Intuitive Surgical Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.